Dexamethasone results

press releases

16 June 2020

Statement from the Chief Investigators: low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19

Comunicado dos Pesquisadores Principais do estudo “Avaliação randomizada de terapias para a COVID-19” (RECOVERY) sobre dexametasona, 16 de junho de 2020

Comunicado de prensa de la Universidad de Oxford: Dexametasona reduce la mortalidad hasta un tercio en pacientes hospitalizados con complicaciones severas por COVID-19

12 April 2023
RECOVERY trial finds that a higher dose of corticosteroids is harmful compared to usual care

haiku.publications

march 2025

Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial published in eClinical Medicine.

4 september 2024

Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial published on medRxiv.

12 april 2023

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label platform trial published in The Lancet.

16 December 2022

The results of higher dose corticosteroids in hospitalised COVID-19 patients with hypoxia but not requiring ventilatory support published on medRxiv.

25 February 2021

Dexamethasone in Hospitalized Patients with Covid-19, published in The New England Journal of Medicine.

2 September 2020

Meta-analysis including the RECOVERY trial published in JAMA .

22 june 2020

Preliminary results of the dexamethasone comparison published on medRxiv.

Cookies on this website